Gene Therapy to Target BCMA for Multiple Myeloma is under clinical development by Asclepius Technology Company Group Suzhou and currently in Phase II for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase II drugs for Multiple Myeloma (Kahler Disease) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gene Therapy to Target BCMA for Multiple Myeloma’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Target BCMA for Multiple Myeloma overview
Gene therapy is under investigation for the treatment of multiple myeloma. The therapeutic candidate comprises of allogeneic NK-92 cells engineered to express chimeric antigen receptor (CAR) with antibody fragment targeting B-cell maturation protein (BCMA/CD269/TNFRSF17) fused to signaling domains. It is developed based on CAR-T cell technology.
For a complete picture of Gene Therapy to Target BCMA for Multiple Myeloma’s drug-specific PTSR and LoA scores, buy the report here.